Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival

BACKGROUND: The development of targeted therapies has undoubtedly broadened therapeutic options for patients with colorectal cancer (CRC). The use of bevacizumab to reduce angiogenesis has been associated with improved clinical outcomes. However, an urgent need for prognostic/predictive biomarkers f...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Paiva, Tadeu Ferreira, de Jesus, Victor Hugo Fonseca, Marques, Raul Amorim, da Costa, Alexandre André Balieiro Anastácio, de Macedo, Mariana Petaccia, Peresi, Patricia Maria, Damascena, Aline, Rossi, Benedito Mauro, Begnami, Maria Dirlei, de Lima, Vladmir Cláudio Cordeiro
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4579833/
https://ncbi.nlm.nih.gov/pubmed/26394830
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1648-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars